沙库巴曲缬沙坦对心力衰竭患者血清胱抑素C及和肽素水平的影响  

Effect of sacubitril/valsartan on serum cystatin C and copeptin levels in patients with heart failure

作　　者：郑淋 ZHENG Lin(Department of Laboratory,Qionghai People′s Hospital,Hainan Province,Qionghai 571400,China)

机构地区：[1]海南省琼海市人民医院检验科,571400

出　　处：《临床合理用药杂志》2023年第34期1-4,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察沙库巴曲缬沙坦对心力衰竭患者血清胱抑素C(CysC)及和肽素水平的影响。方法选取2020年1月—2021年1月琼海市人民医院收治的心力衰竭患者100例,采用随机数字表法分为观察组和对照组,每组50例。2组患者均接受常规抗心力衰竭治疗,在此基础上,对照组应用盐酸贝那普利片治疗,观察组应用沙库巴曲缬沙坦治疗,2组均治疗60 d。比较2组临床疗效,治疗前后血清CysC、和肽素水平、6 min步行距离(6MWD)及不良事件。结果观察组治疗总有效率为96.00%,高于对照组的74.00%(χ^(2)=9.490,P=0.002)。治疗60 d后,2组血清CysC、和肽素水平低于治疗前,6MWD长于治疗前,且观察组低于/长于对照组(P<0.01)。观察组不良事件总发生率为4.00%,与对照组的8.00%比较差异无统计学意义(χ^(2)=0.177,P=0.673)。结论沙库巴曲缬沙坦治疗心力衰竭可显著改善疾病症状,缓解并抑制心室重构,有效降低血清CysC及和肽素水平,提高患者运动耐量,且不良事件发生风险低,安全性较高。Objective To observe the effect of sacubitril/valsartan on serum cystatin C(CysC)and copeptin levels in patients with heart failure.Methods A total of 100 patients with heart failure admitted to Qionghai People′s Hospital from January 2020 to January 2021 were randomly divided into observation group and control group,with 50 cases in each group.Both groups received conventional anti heart failure treatment,on the basis of this,the control group was treated with benazepril hydrochloride tablets,and the observation group was treated with sacubitril/valsartan,both groups were treated for 60 days.The clinical efficacy,the levels of serum CysC and copeptin,6 minutes walking distance(6MWD)before and after treatment and adverse events were compared between the two groups.Results The total effective rate of the observation group was 96.00%,which was higher than 74.00%of the control group(χ^(2)=9.490,P=0.002).After 60 days of treatment,serum CysC and copeptin in the two groups were lower than before treatment,6MWD in the two groups was longer than before treatment,and the observation group was lower/longer than the control group(P<0.01).The total incidence of adverse events in the observation group was 4.00%,and there was no significant difference compared with 8.00%in the control group(χ^(2)=0.177,P=0.673).Conclusion Sacubitril/valsartan in the treatment of heart failure can significantly improve disease symptoms,relieve and inhibit ventricular remodeling,effectively reduce serum CysC and copeptin levels,promote the exercise tolerance of patients and has low risk of adverse events and high safety.

关 键 词：心力衰竭 沙库巴曲缬沙坦 胱抑素C 和肽素 

分 类 号：R541.6[医药卫生—心血管疾病]